Home › Gilead paying up to $1.2B for Nimbus unit, drug candidate
 

Keywords :   


Gilead paying up to $1.2B for Nimbus unit, drug candidate

2016-04-04 22:15:41| Biotech - Topix.net

Biologic drugmaker Gilead Sciences Inc. said Monday that it will buy a subsidiary of Nimbus Therapeutics LLC and its experimental pill for an increasingly common metabolic disorder that causes life-threatening fat buildup in the liver. Gilead, based in Foster City, California, will pay $400 million for Nimbus Apollo Inc. Parent company Nimbus Therapeutics, based in Cambridge, Massachusetts, could receive another $800 million if Nimbus Apollo's drug development program meets certain milestones in testing results and medicine approval and sales.

Tags: unit drug candidate paying

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
08.11African swine fever, labor and trade top of mind for Canadian pork industry
08.11Tech giants dominate U.S. streaming platform market
08.11Warner Bros. Discovery adds 7.2 million DTC subscribers in 3Q 2024
08.11Polyurea-Based Lining is Key to GRE Pipeline Rehab Project in UAE
08.11Parents paying over the odds for baby milk, watchdog warns
08.11Sports fans driving global growth in streaming services
08.11TiVo OS footprint approaching one million activated Smart TVs
08.11The Entertainer axes new shops after Budget tax rise
More »